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This experiment was designed to assess the capacity of dietary genistein (GEN), to attenuate bone loss in ovariectomized (OVX)
and ovary-intact VCD-treated mice. Pretreatment of mice with 4-vinylcyclohexene diepoxide (VCD) gradually and selectively
destroys ovarian follicles whilst leaving ovarian androgen-producing cells largely intact. VCD induces a perimenopause-like
conditionpriortotheonsetofreproductiveacyclicity.Sixteen-week-oldC57BL/6Jmicewererandomizedtoﬁvetreatmentgroups:
s h a m ( S H M ) ,O V X ,S H M+V C D ,O V X+G E N ,a n dS H M+V C D+G E N .I nv i v o ,b l o o ds a m p l e sw e r ed r a w nf o rh o r m o n e
and isoﬂavone analyses, estrous cycles were monitored, and X-ray imaging was performed to assess changes in bone parameters.
Following sacriﬁce, ovaries were assessed histologically, bone microarchitecture was evaluated via microcomputed tomography,
and bone mechanical properties were measured. Some eﬀects of GEN were observed in OVX mice, but GEN eﬀects were not able
to be evaluated in VCD-treated mice due to the subtle diminution of bone during the 4 months of this experiment.
1.Introduction
Perimenopause is the transitional period in a woman’s life
characterized by the onset of irregular menstruation before
permanent cessation of the menses or menopause. Estrogen
(E2) insuﬃciency related to menopause has been shown
to be a major pathological factor in the development and
progression of osteoporosis, particularly in women that
fall short of optimizing their genetic potential for peak
bone mass in earlier adulthood. Although Premarin (conju-
gated estrogens) was the second most frequently prescribed
medication in the United States in the year 2000 [1], its
therapeutic use for the prevention or attenuation of bone
loss in postmenopausal women is currently a controversial
option given its potential for associated health risks [2,
3]. Based on outcomes of the Women’s Health Initiative
(WHI) study, the prescription of estrogen replacement
therapy or estrogen in conjunction with progestin may not
always be the best, safest, or preferred means by which
to prevent pathologic bone loss during menopause [4].
General recommendations following the WHI stipulated
that women should carefully weigh the beneﬁts and risks
of hormone replacement therapy and possibly consider
nonhormonal options for the treatment of osteoporosis.
Interest subsequently increased in various phytoestrogens,
or natural plant-derived estrogen-like compounds, as a
dietary therapeutic to facilitate the attenuation of bone
loss [5]. Genistein (GEN) is one of a variety of isoﬂavone2 Journal of Osteoporosis
phytoestrogens derived from soybeans; it has been used in
a number of food, beverage, and supplement formulations
on the premise of delivering health beneﬁts via its potential
to act as a natural selective estrogen receptor modulator
(SERM) [6] with partial estrogen receptor agonism that is
less likely to perturb reproductive tissues.
To date, GEN research has yielded variable results and
there is no consensus on the magnitude of its eﬀect(s) on
bone [7–10]. In human studies and animal experiments
of estrogen deﬁciency, GEN has been shown to exert
anabolic actions on bone [11–14] or attenuate bone loss via
antiresorptive eﬀects both as a puriﬁed compound [15–17]
andasacomponentofsoyisoﬂavonemixtures[18–20].GEN
has also exhibited anabolic eﬀects on osteoblastic cells [21]
and suppressive activities on osteoclasts [22, 23]. Overall,
the therapeutic value of isoﬂavones to bone preservation
has been more consistently demonstrated in ovariectomized
r odentsv ersusstudiesinpostmenopausalwomen[24].Some
of the disparities in human versus rodent isoﬂavone studies
may relate to the route of administration onset.
In preclinical rodent experiments, bilateral ovariectomy
is currently the most common method employed for bring-
ing about a state of diminished E2 to simulate menopausal
bone loss. However, ablation of the ovaries causes an unnat-
urally abrupt decline in circulating estrogens and ovarian-
synthesized androgens. Inducing ovarian senescence via
gradual follicle depletion may greatly improve the physiolog-
ical relevance of hormone-linked bone loss experiments in
animalsbymoreaccuratelysimulatingthehormonalchanges
that take place in women as they transition to menopause
[25]. Repeated chemical treatments with 4-vinylcyclohexene
diepoxide (VCD) have been shown to induce progressive
ovarian preantral follicle atresia in mice that gradually leads
to a signiﬁcantly diminished capacity for ovarian estrogen
secretion [25–27]. Whereas OVX mice more closely simulate
the hormonal proﬁle of women that have undergone surgical
menopause, VCD-treated mice remain ovary-intact with an
established residual ovarian androgen-producing capacity
[27, 28]. To date, one study by Wright et al. [25]h a s
demonstratedsigniﬁcantbonelossinmicetreatedatayoung
age with VCD.
As u m m a r yo fp r o s p e c t i v es t u d i e so nB M Dc h a n g e sd u r -
ing perimenopause indicates that annual percentage declines
are often similar to those of women in the early stages
of menopause when bone turnover is markedly elevated
[29]. Other human data also provide evidence of signiﬁcant
bone loss during the perimenopausal period [30–33]w h i c h
may be attributable to hypoestrogenic oligomenorrhea [34]
(infrequent or light menstruation associated with low estro-
gen levels) experienced by many women and increasing
gonadotropin levels [35]. Similar to hormone replacement
therapy [36, 37], two human studies have suggested that
dietary GEN may be more likely to demonstrate a favorable
eﬀect if administered earlier, rather than later on, in the
menopausal period [11, 24]. Furthermore, it has been
proposed that during perimenopause and early menopause
estrogen receptor number and responsiveness may be more
conducive to an isoﬂavone-mediated eﬀect [38]. These
considerations stimulated our interest in the VCD-treated
mouse that transitions through a perimenopause-like period
prior to reproductive acyclicity. The aim of this experiment
was to assess the potential of GEN to attenuate bone loss in
the traditional OVX mouse model and in the novel VCD-
treated mouse that transitions to a menopause-like state.
2.MaterialsandMethods
2.1. Animals and Preparatory Procedures. Sixteen-week-old
female C57BL/6J mice (total “n” of 100) with mean (±SD)
body weights of 20.32 ±1.10g were purchased from Jackson
Laboratories (JAX, West Sacramento, CA). After purchase,
all mice continued to be housed at JAX’s animal facilities
for a 3-week period so that preparatory treatments could be
implemented prior to shipment.
In two of the treatment groups destined for sham
surgeries (SHM), the chemical 4-vinylcyclohexene diepoxide
(VCD) was administered by JAX animal technicians once
dailyfor15-d(startingdayone)viaintraperitonealinjections
at a dose of 160mg/kg/day (Sigma-Alrdrich; St. Louis, MO).
A sesame oil vehicle was used as a placebo treatment for
the remaining three groups. On day 18, three groups of
mice underwent sham (SHM) surgeries and two groups were
subjected to bilateral ovariectomy (OVX). In accordance
with these initial treatments and the assigned GEN dietary
regime for one SHM and one OVX group, rats were allocated
to one of the following groups: (1) SHM, (2) OVX, (3) S +
V( S H M+V C D ) ,( 4 )O+G( O V X+G E N ) ,a n d( 5 )S V G
( S H M+V C D+G E N ) .
Upon arrival at our animal facility, mice were housed
5/cage, under conditions of controlled lighting (12-hour
light:dark photoperiod), constant temperature (22 ± 2◦C),
and with free access to food and water. All mice were
acclimated for 1-week prior to exposure to any type of
procedures/measurements.
2.2. Diets. From day one of the experiment, all ﬁve groups
of mice (16-wk-old) were fed a casein-based diet (5K96;
Testdiet, Richmond, IN) formulated to consistently measure
<1 ppm total isoﬂavones (aglycone equivalents of genistein,
daidzein, and glycitein). Following OVX/SHM surgeries, at
which time the mice had reached 18-wk-old, two groups of
mice (i.e., O + G and SVG) were supplemented with the
aglyconeformoftheisoﬂavoneGEN.TheGENwasdelivered
to mice via the oral route as a 0.04% (w/w) constituent
of the pelleted 5K96 diet supplying ∼55mgGEN/kg body
weight/day. This represents the average level of the dosage
range reported to stimulate bioactivity in rodents (i.e., 10 to
100mg/kgbwt/day) [39]. The GEN used to enrich the diet
was in crystalline powder form and >99% pure (Product #
G-6055, LC Laboratories, Woburn, MA).
2.3. Experimental Design. This study was longitudinal in
design; in vivo bone imaging and blood sample collections
were performed at intervals depicted in the experimental
time line (Figure 1). The body weights of mice were recorded
weekly and prior to all experimental procedures from the
start of the experiment until the time of euthanizationJournal of Osteoporosis 3
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Figure 1: Experimental timeline.
(18.5-wk later). Sacriﬁce was via exsanguination followed by
cervical dislocation under anesthesia when the mice were
33.5-wk-old. All experimental procedures complied with
protocols were approved by Indiana University School of
Medicine and Purdue University Care and Use Committee
guidelines.
2.4. Reproductive Cyclicity. Estrous cycle stage was deter-
mined by vaginal cytology in SHM (cycling control),
S+V,andSVGtreatmentgroupsthroughouttheexperiment
to verify the disruption and eventual cessation of normal
estrous cycling resulting from VCD treatment. Acyclicity was
deﬁned as 10 consecutive days of diestrus. A vaginal lavage
technique was used for cytology evaluations.
2.5. Bone Imaging
2.5.1. In Vivo DXA. AL u n a rP I X I m u s I Id e n s i t o m e t e r( G E
Medical Systems) was utilized to obtain data from pro-
jectional images of the right hindlimb of mice to assess
areal BMD (mg/cm2), BMC (mg), and bone area (cm2)
8-wk after ovariectomy. BMC was normalized by body
weight (BWT) to adjust for diﬀerences in body size [40].
Mice were immobilized for the scanning procedure by gas
inhalation (1.5–2.0% isoﬂurane in 1.5L/min O2) and placed
in prone position on the scanning stage. The entire right
hindlimb region, up to but excluding the pelvic girdle,
was selected for analysis rather than individual bones (i.e.,
femora, tibiae). The coeﬃcients of variation (CV%) for
DXA analyses (BMD, 0.73%; BMC, 1.16%; area, 0.97%)
were based on 10 consecutive in vivo hindlimb scans with
complete repositioning of the animal between scans.
2.5.2. In Vivo pQCT. The proximal metaphyses of the left
tibiae of mice were measured longitudinally by repeated in
vivo peripheral quantitative computed tomography (pQCT)
scans at 5-, 9-, and 15-wk of the experiment. Each mouse
wasanesthetized(i.e.,3%–4%isoﬂuranein1.5L/minO2)for
induction to eﬀect before being placed in a supine position
Proximal TFJ
reference line (ROI_1)
0.25 mm (ROI_2)
50 mm (ROI_3)
Distal tibia
Fibula
Figure 2: pQCT regions of interest in the proximal tibiae of mice.
Distances of scanned slices from the proximal tibioﬁbular junction.
on a heated pad with its nose exposed to a tube supplying
isoﬂurane gas (i.e., 1.5%–2.0% in 1.5L/min O2) to maintain
light anesthesia. The left hindlimb was extended in the
caudal direction and centered and secured with adhesive
tape onto a 1cm wide support that protruded into the
pQCT gantry. The right forelimb was extended cephalically
and taped in place to counterbalance, align, and further
securetheanimal’sbodyduringscanning.Basedonaninitial
cross-sectional scout-scan, a ﬁrst landmark reference slice
(ROI 1)wasplacedunderthegrowthplateinalignmentwith
the most distal aspect of the proximal tibioﬁbular junction
(TFJ) (Figure 2). Images for analyses were obtained from a
second and third slice placed 0.25mm (ROI 2) and 0.50mm
(ROI 3) distal to the ﬁrst slice, respectively. Correct targeting
of the ROIs was conﬁrmed when the ROI 1 image displayed
contiguity between the proximal tibia and ﬁbula, and when
the RIO 2 image from the same scan series exhibited the
separation of these two bones from each other.
Single slice cross-sections of bone 0.26mm thick were
imaged with a XCT Research SA + pQCT (Norland-Stratec4 Journal of Osteoporosis
Medizintechnik GmbH, Birkenfel, Germany) at an isotropic
voxel resolution of 70 μm. The pQCT was programmed to
use cortmode 1 to separate cortical voxels from trabecular
voxels, contmode 1 to detect the outer bone contour, and
peelmode 2 to deﬁnethe trabecularcompartment.An atten-
uation threshold of 900mg/cm3 was selected to distinguish
cortical from trabecular bone [41], whereas soft tissue was
diﬀerentiatedfromboneatathreshold300mg/cm3.Analyses
of pQCT images were performed using the manufacturer’s
integrated XCT software package (version 5.50) that records
parameters in a loop project.
A CV% was calculated (i.e., 100 × [standard devia-
tion/mean])basedontheaveragevaluesof20separatepQCT
scans (with repositioning between each scan) acquired at
each ROI. Five in vivo scans per animal in four mice were
performed for this purpose. The CVs at ROI 2 for total,
cortical, and trabecular BMD were 1.6%, 1.6%, and 2.1%
respectively. The CV for cortical thickness at ROI 2w a s
much higher at 27.2%.
2.5.3. Ex Vivo μCT. A high-resolution desktop microtomo-
graphic imaging system with a microfocus X-ray tube as
as o u r c e( μCT40; Scanco Medical, Basserdorf, Switzerland)
was used to image contiguous transverse slices of trabecular
bone at the distal femoral metaphysis and the ﬁfth lumbar
v e r t e b r a lb o d y( L 5 )a sw e l la sc o r t i c a lb o n ea tt h ef e m o r a l
midshaft. Measurements at each location on the femur and
vertebral body were performed on six randomly selected
samples per treatment group at a nominal isotropic voxel
resolution of 6μma n d1 2 μm, respectively. Images were
segmented using a constrained 3D Gaussian ﬁlter (sigma
= 0.8 and support = 1 pixel). Site-speciﬁc thresholds that
were 30% and 22.4% of the maximal gray-scale value were
selected to adjust for variations in absorption coeﬃcients
between cortical and trabecular bone, respectively [42]. A
50-slice region spanning 300μm in the midshaft of the
femoral diaphysis was scanned. Trabecular measurements in
the distal femoral metaphysis were conﬁned to 250 slices
(a region of 1500μm in length) in the secondary spongiosa
located 408μm proximal to the physeal-metaphyseal junc-
tion landmark. Microtomographic images were collected
over a 2220μm long mid-vertebral region between the
cranial and caudal endplates of the L5 vertebral body.
Trabeculae of the left distal femoral metaphysis and ﬁfth
lumbar vertebral body (L5) of mice were evaluated for bone
volume fraction (BV/TV, %) and direct 3D indices including
trabecular thickness (Tb.Th, μm), trabecular separation
(Tb.Sp, μm), and trabecular number (Tb.N, mm−1). μCT
cortical bone parameters assessed included volume (BV,
mm3), area (BA, mm2), and cortical thickness (Ct.Th,
mm).
The μCT CV% (based on 10 repeat scans of one sample
with complete repositioning between scans) acquired at
each site of interest revealed a precision of <3% and <1%,
respectively, at the distal metaphysis and midshaft of the
femur for all parameters reported. The CV% was <2% for
all vertebral μCT parameters, with the exception of 4.2% for
BV/TV.
2.6. Three-Point Biomechanical Testing. Mechanical testing
was performed on a miniature materials-testing machine
(Vitrodyne V1000: Liveco, Inc., Burlington, VT, USA) with
a force resolution of 0.05N. All bones for mechanical
testing were stored at −20
◦C. Prior to testing, samples were
deﬂeshed and rehydrated overnight in 0.9% saline at room
temperature[43].Supportsonwhichthebonesrestedduring
testing spanned 8.5mm and 11.2mm for the right femora
and left tibiae, respectively. A small compressive stabilizing
preload of <0.1N was applied to specimens prior to the start
of the test. Bones were loaded centrally in the most stable
orientation, (i.e., anterior to posterior for the femur, and
posterior to anterior for the tibia) at the midshaft of the
diaphyses using a crosshead speed of 0.2mm/sec. The yield
point was deﬁned using a 0.015mm oﬀset parallel to the
linear elastic region of the curve. Force-displacement data,
collected by the software every 0.02sec during each test,
was imported into an Excel worksheet formatted to generate
the structural parameters and mechanical properties of the
bones. These included ultimate force (N), failure (breaking)
force (N), yield force (N), stiﬀness (N/mm), and energy to
ultimate force (mJ), energy to failure (mJ). Total bone length
(mm), measured using digital calipers (Mitutoyo, 0.01mm
resolution), was also included with bone mechanical data.
2.7. Blood Collection. Small quantities of blood were col-
lected periodically (≤200μLa t>14-day intervals [44]) in
Microtainer Plasma Separator Tubes (Beckton-Dickson, NJ,
USA) during the experiment at time points coinciding
with in vivo x-ray scan measurements. A submandibular
vein puncture technique was employed for all survival
blood collections. Light anesthesia was induced via gas
inhalation (Isoﬂo, Abbott Laboratories, North Chicago, IL)
after which the mice were momentarily immobilized and
scruﬀed and the underlying vasculature was pierced with a
lancet (GoldenRod, Medipoint Inc. Mineola, NY, USA) to
draw blood droplets. To permit collection of the maximum
volume of blood available at the end of the study, a terminal
retro-orbital exsanguination procedure was performed while
the animals were under deep sedation.
2.8. Hormone Analysis. Plasma levels of androstenedione
(ANDRO) and 17β estradiol (E2) were determined via
duplicate assays using radioimmunoassay (RIA) kits (Diag-
nostic Products Inc., Los Angeles, CA). Follicle stimulating
hormone (FSH) plasma levels were determined using a
National Hormone and Pituitary Distribution Program
RIA kit. Results of all RIAs were calculated by four-
parameter logistic analysis using the AssayZap software
program (Biosoft, Ferguson, MO). Respective sensitivity
and intraassay coeﬃcients of variation were 17β-estradiol,
1.25pg/mL, and 2.46%; androstenedione: 30pg/mL and
7.25%; FSH: 100pg/mL and 1.71%.
2.9. Isoﬂavone Analysis. Plasma isoﬂavone concentrations
weredetermined by reversephase LC-electrosprayionization
massspectrometryonatriplequadrupolemassspectrometerJournal of Osteoporosis 5
(ABI-Sciex 4000 Qtrap LC/MS/MS system, Applied Biosys-
tems, San Jose, CA) using a modiﬁcation (i.e., liquid-liquid
extraction) of the method described previously by Coward
et al. [45]. Due to the very small aliquots of plasma available
from each mouse, two pooled samples from each cage were
analyzed and results were averaged.
2.10. Statistics. The SAS statistical program (version 9.1,
SAS Institute, Cary, NC) was used to analyze all data.
Homogeneity of variance (Levene’s test) and normality
(Shapiro-Wilk’s W test) were routinely assessed to ensure
that the assumptions of ANOVA tests were met. One-way
ANOVA was used for parametric data, and when diﬀerences
were statistically signiﬁcant (P<. 05), pairwise comparisons
among means were performed using the post hoc Tukey-
Kramer procedure. Nonparametric data were analyzed using
the Kruskal-Wallis test (the nonparametric analog of a
one-way-ANOVA).Statisticallydiﬀerentnonparametrictests
(P<. 05)werecomparedusingDunn’sposthoctest.Dataare
reported as group means ± SEM unless stated otherwise.
3. Results
3.1. Overview of the Animals. Four mice died before being
shipped from JAX laboratories and two mice died during
thestudy.Recordsdocumentingthegeneraloutwardappear-
ance, health, and behavior of the mice were maintained
throughout the experiment. At necropsy it was determined
that some mice had gross gonadal abnormalities (see ovary
results); however, aﬀected animals were eliminated from all
but the food consumption analyses due to the nature of
the group-housed data. As a consequence, group data were
limited to SHM (n = 11), OVX (n = 15), S + V (n = 12), O
+G( n = 18), and SVG (n = 12) mice.
3.2. Body Weights. Mean body weights were signiﬁcantly
diﬀerentamonggroupsatthebeginningandendofthestudy
(Figure 3). Initially S + V mice weighed signiﬁcantly more
than the SHM rats and no other groups were diﬀerent from
the SHM and S + V treatment groups. At the end of the
study ovariectomized mice (OVX and O + G) had gained the
highest percentage of weight and were signiﬁcantly heavier
than the SHM group, but not diﬀerent from VCD-treated
mice.
3.3. Food Consumption. Ovariectomy increased the amount
of food consumed in the OVX group compared to the SHM
and S + V mice (P<. 05; data not shown). No food
consumption diﬀerences existed between other treatment
groups. Daily genistein consumption, normalized for body
weight, was comparable between O + G and SVG mice.
3.4. Isoﬂavone Analysis. Blood collected from mice during
the terminal blood draw at 18-wk was analyzed for plasma
concentrations of numerous isoﬂavones including genistein
(GEN), daidzein, dihydrodaidzein, O-desmethylangolensin
(O-DMA), equol, glycitein, formononetin, coumestrol,
biochanin A, and 6-OH O-DMA. With the exception of the
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highly signiﬁcant diﬀerences in the plasma GEN concentra-
tions among groups (P<. 0001) that were fed versus not fed
a GEN-enriched diet (Figure 4), no diﬀerences were detected
among treatment groups for the other isoﬂavones analyzed
(data not shown). Plasma GEN levels in O + G and SVG
treatment groups were not statistically diﬀerent from each
other.
3.5. Reproductive Cyclicity. The S + V and SVG mice
that were administered VCD for 15 consecutive days were
observed to cease reproductive cycling at a mean(±SEM)
of 80 ± 9a n d8 6± 8 days after the initial VCD injection
(P>. 05; data not shown). By comparison, the SHM6 Journal of Osteoporosis
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mice included in all analyses demonstrated relatively regular
estrous cycles that ranged from 4 to 5 days in duration.
3.6. Uterine Weights. Both ovariectomy and VCD treatment
resulted in uterine atrophy relative to the SHM mice (P<
.0001). Ovariectomy caused the greatest mean decrease in
uterine weight (>75% versus SHM) while VCD treatment
reduced mean uterine weight by at least 50% versus SHM.
Groups treated with GEN (O + G and SVG) did not exhibit
increased uterine weight/body weights compared to their
non-GEN-treated counterparts, indicating that GEN did not
exert a uterotrophic eﬀect in this study (data not shown).
3.7. Ovaries. At necropsy, ovaries of intact mice were
removed from the surrounding fat pad for further analyses.
Some pathologic abnormalities in a number of ovaries
were observed at this point; a number of mice developed
substantial ovarian ﬂuid-ﬁlled bursal sac expansions (rang-
ing in diameter from 0.5- to 1.0cm), some unilaterally,
some bilaterally, that were associated with severely atrophied
ovarian tissue at the aﬀected site(s). Mice belonging to the
SHM, S + V, and SVG groups were aﬀected (n = 8, n = 7
and n = 7, resp.) and these animals were eliminated from the
analyses. Also, two OVX mice identiﬁed as having an ovary
inadvertently left in place and two O + G mice with large
ﬂuid ﬁlled sacs at the end of the fallopian tubes but with no
ovarian tissue present were excluded from the results.
Ovaries from the remaining healthy animals underwent
sectioning for histological follicle counts (Figure 5). Since
there was no signiﬁcant diﬀerence between the VCD-
treated S + V and SVG mice (based on an F-test that
met ANOVA assumptions), they were grouped together
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One-way ANOVAs performed at each time period were signiﬁcant
(P<. 0001). Values represent means ± SEM. Diﬀerent symbols
signify diﬀerences among groups based on the Tukey-Kramer post
hocprocedureasfollows:
∗ SHM<allothergroups;
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for comparison against the SHM controls using the non-
parametric Wilcoxon-Mann-Whitney Test which revealed a
signiﬁcant diﬀerence between control and VCD-treated mice
(P<. 0001) for all types of follicle counts performed (i.e.,
primordial, small primary, large primary, secondary, and
antral). Ovaries were also examined for corpora lutea; the
ovaries of cycling mice revealed the presence of corpora
lutea(100%),whereastheywereabsentfromallVCD-treated
mice.SHMmiceweregenerallycharacterizedbythepresence
of antral follicles, whereas only one of the total number of
VCD-treated mice exhibited the presence of an antral follicle
(S + V), which was observed to be atretic (i.e., degenerated)
and therefore included in all analyses.
3.8. Hormone Analyses. Plasma concentrations of FSH
remainedconsistentlylowintheSHMcontrolmicethrough-
out the experiment (Figure 6). FSH concentrations in
ovariectomized mice (OVX and O + G) spiked markedly
by wk-5 and remained elevated throughout the remaining
weeks of the experiment. VCD-treated mice displayed ele-
vated concentrations of FSH that were signiﬁcantly higher
than sham controls at 5-wk, yet signiﬁcantly lower thanJournal of Osteoporosis 7
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Figure 7: Treatment eﬀects on plasma androgen (ANDRO) concentrations of mice. The panel of boxplots illustrates the group medians
(line within the box), means (+), interquartile range (length of the box), and the minimum and maximum values (extended whiskers) at
each time point assessed. Data represent n = 3–6 samples/group. The Kruskal-Wallis test revealed the following P-values: wk-5, P = .3732;
wk-9, P = .0387; wk-11, P = .0142; wk-18, P = .0593.
ovariectomized mice. During wk-9 to wk-11 FSH grad-
ually began to increase as the animals transitioned to a
menopause-like state and by wk-18 the VCD-treated mice
had circulating FSH concentrations comparable to the OVX
mice.
Circulating concentrations of 17β-estradiol averaged as
high as 6.35pg/mL and 4.86pg/mL in S + V and SVG
mice (n = 4/group), respectively, at wk-11, after which
levels plummeted to nondetectable levels by wk-18. The 17β-
estradiol data are not presented as it is somewhat diﬃcult
to interpret due to diﬀerences in estrous cycle stage among
animals as they transitioned to reproductive senescence.
OVX and O + G mice (n = 6-7/group) synthesized
comparatively low average levels of E2 at the time points we
m e a s u r e d ;h o w e v e r ,b yw k - 1 1i nO+Ga n db yw k - 1 8i n
OVX and mice, E2 was below the detection limit and only
above the detection limit in sham controls. Plasma ANDRO
concentrations from wk = 9–18 were detectable in most
SHM-and VCD-treated mice and relatively undetectable in
ovariectomized mice (Figure 7).
3.9. DXA. Ovariectomy, both with and without GEN treat-
ment, decreased BMD and BMC normalized for body size
compared to SHM 8-wk postovariectomy (Table 1). There
was no diﬀerence between BMD and BMC/BWT for VCD-
treated versus SHM mice. Bone area was not diﬀerent among
treatments.
3.10.pQCT. LongitudinalpQCTscanningdatafromthetwo
ROIs below the reference line at the tibioﬁbular junction
(TFJ) revealed similar diﬀerences between the two ROI
sites. Herein we present data from 0.25mm below the TFJ
(Figure 8).GENappearedtobeassociatedwithanincreasein
totalBMD,corticalthickness,andcorticaldensitybythetime
of the last pQCT scan in O + G versus OVX mice. The VCD-
treated mice retained a similar cortical thickness and BMDs
similar to SHM mice up to 30-wk-age or 15-wk after the
initiation of VCD dosing. A coeﬃcient of variation (CV%)
was calculated (i.e.,100 × [standard deviation/mean]) based
on the average values of 20 separate pQCT scans (with8 Journal of Osteoporosis
Table 1: DXA parameters of the hindlimb assessed in vivo.
Parameters, (units) SHM OVX S + V O + G SVG
BMD, (mg/cm2)4 9 .9 ±0.4 46.7 ± 0.4∗ 48.1 ± 0.6 46.9 ±0.9
∗ 48.8 ±0.4
BMC/BWT 2.74 ±0.03 2.35 ±0.04
∗∗ 2.69 ± 0.03 2.45 ±0.05
∗∗ 2.65 ± 0.04
Area, (cm2)1 .160 ±0.001 1.211 ±0.011 1.195 ±0.001 1.206 ±0.014 1.193 ±0.019
Data represent the mean ± SEM. ∗P<0.001 versus SHM; ∗∗P<. 0001 versus SHM-and VCD-treated groups.
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Figure 8: Treatment eﬀects on the bone mineral density and cortical thickness of the proximal tibial metaphysis as assessed longitudinally
in vivo via pQCT. Data represent the mean ± SEM values imaged 0.25mm distal to the tibioﬁbular junction. Symbols indicate signiﬁcantly
diﬀerent means (P<. 005) as assessed by a one-way ANOVA and subsequent post hoc Tukey tests as follows: ∗ group versus SHM;
† group
versus VCD-treated mice (S + V and SVG);
§ group versus SVG;
‡ group vs. O + G; # group versus SVG.
repositioning between each scan) acquired at each ROI. Five
in vivo scans per animal in four mice were performedfor this
purpose. The CVs at ROI 2 for total, cortical and trabecular
BMD were 1.6%, 1.6%, and 2.1%, respectively. The CV
for cortical thickness at ROI 2 was much higher at 27.2%;
however, all signiﬁcant diﬀerences among groups for cortical
thickness were almost twice the CV% for this parameter.
3.11. μCT. Trabecular bone architecture in the distal femur
was similar among all groups of mice regardless of
SHM/OVX status (16-wks duration) and/or VCD treatment
(18-wk after the start of dosing) and/or dietary GEN
supplementation (for 18-wks). In contrast, trabecular bone
in the ﬁfth lumbar (L5) vertebral body exhibited a number
of diﬀerences among treatments (Table 2). L5 bone volumeJournal of Osteoporosis 9
Table 2: Ex vivo microcomputed tomography measures of bone microarchitectural changes in treated mice.
μCT parameters (units) Treatments (n = 6/group)
SHM OVX S + V O + G SVG Pooled SEM P-value
L5 Vertebral body: trabecular
BV/TV, (%) 18.4a 12.4c 15.1ab 14.5bc 15.7b 0.6 <0.0001
BV, (mm3)0 .472a 0.354b 0.394ab 0.396ab 0.426ab 0.019 <0.005
Tb.N, (mm−1)3 .32a 2.77b 2.94ab 2.76b 2.97ab 0.116 <0.05
Tb.Th, (μm) 55a 47b 55a 56a 55a 1 <0.0001
Tb.Sp, (μm) 305 367 342 367 341 16 NS
Distal femur: trabecular
BV/TV, (%) 2.62 2.05 2.39 1.90 2.00 0.08 NS
BV, (mm3) 0.066 0.057 0.062 0.46 0.53 0.01 NS
Tb.N, (mm−1) 2.21 1.94 2.01 1.91 2.07 0.20 NS
Tb.Th, (μm) 41 42 44 43 40 2 NS
Tb.Sp, (μm) 446 522 500 524 483 22 NS
Midshaft femur: cortical
Area (mm2)0 .838a 0.770b 0.829ab 0.806ab 0.837a 0.014 <0.05
Ct.Th, (μm) 200a 176b 194a 192a 196a 0.003 <0.001
BV (mm3)0 .242a 0.222b 0.239a 0.231ab 0.241a 0.004 <0.05
Data represent the group means. P-values are for one-way ANOVA tests. Diﬀerent letters indicate means that are statistically diﬀerent based on Tukey-Kramer
post hoc test.
fraction (BV/TV) in OVX and O + G groups was decreased
compared to SHM mice. The S + V mice retained a
comparable vertebral BV/TV versus SHM controls; however,
this parameter was compromised in SVG mice versus SHM.
Fifth lumbar Tb.Th was equivalent among all groups with
the exception of the OVX mice in which trabecular thinning
was detected. The OVX mice that received GEN (O + G)
appeared to have been protected against this occurrence.
Apart from diﬀerences in BV/TV, the VCD-treated mice were
similar to SHM mice with respect to vertebral trabeculae
morphology.Atthemidshaftofthefemur,theOVXmicedis-
playedasigniﬁcantlydiminished corticalenvelopecompared
to all other groups, with the O + G group of mice appearing
to have been protected against cortical thinning by the addi-
tion of dietary GEN. Cortical bone area and volume at the
midshaft was also signiﬁcantly decreased in OVX mice com-
pared to SHM, whereas other treatment groups were not.
3.12. Mechanical Testing. Three-point bending tests of the
tibiae did not resolve any diﬀerences in whole bone strength
parameters pertaining to ovariectomy, VCD treatment, or
dietary GEN exposure under our test conditions (Table 3).
Tibia length was increased in OVX mice relative to SHM and
SVG mice. VCD-treated mice exhibited similar bone lengths
to SHM animals. Femur mechanical testing revealed that
the OVX mice had less cortical bone strength as evidenced
by the signiﬁcant reductions in yield force, ultimate force,
and failure force parameters compared to SHM controls.
Dietary GEN was associated with an increase in the ultimate
load withstood by the femoral midshaft in O + G versus
OVX mice. The structural strength of the femurs of VCD-
treated mice remained similar to SHM mice 18-wks after the
initiation of VCD dosing, and it was not possible to assess
any eﬀects of GEN in these animals at that endpoint.
4. Discussion
This study examined two diﬀerent murine models of dimin-
ished estrogen-producing capacity that reach a menopausal-
like state. The ﬁrst is the traditional OVX mouse that
is a model of surgically-induced menopause. The second
more recently developed VCD-treated mouse is a model
of chemically-induced menopause. The goal of this study
was to assess the capacity of GEN supplementation to
attenuate bone loss in each of these models. Whereas the
amount of bone loss in mice attributable to ovariectomy-
induced menopause was signiﬁcant in relation to the SHM
controls, the bones of VCD-treated mice did not appreciably
change in relation to SHM controls over the duration of
this experiment. These results suggest that, in the absence
of ovarian estrogen, ovarian testosterone in VCD-treated
mice may attenuate bone loss and delay detrimental changes
in the skeleton. GEN was associated with some positive
eﬀects on the bones of O + G mice compared to OVX
mice including a higher trabecular BMD (proximal tibia)
as well as improvements in trabecular (vertebral) and
cortical (femoral) architecture and a structural strength
parameter(femur)comparabletoSHMlevels.Thedownside
to assessing the eﬀects of GEN in the OVX model is
that it simulates an unnatural and sudden transition to
menopause. Less than 13% of women undergo surgical
oophorectomy which results in immediate sex hormone
depletion [46] .T h er e l a t i v el a c ko fb o n el o s si nV C D - t r e a t e d
mice versus SHM controls during the chemically-induced
perimenopausal-menopausal period raised some interesting
questions in relation to estrogen-deﬁcient animal models for
bone research. However, during the time of this experiment
it was not possible to establish any eﬀect of GEN on VCD-
treated mice.10 Journal of Osteoporosis
Table 3: Bone length and mechanical strength of the femur and tibia of mice during ex vivo three-point testing.
Parameters, (units) Treatments
SHM OVX S + V O + G SVG P-value
Right Femur (n = 11) (n = 12) (n = 8) (n = 14) (n = 9)
Bone length, (mm) 15.81 ±0.02b 16.26 ±0.02a 15.92 ±0.02ab 16.22 ±0.03a 15.76 ±0.03b <.0001
Ultimate Force, (N) 16.0 ±0.3a 13.4 ±0.3b 16.1 ±0.6a 15.7 ±0.5a 16.6 ±0.3a <.0001
Failure Force, (N) 12.1 ±1.1a 5.8 ±1.0b 9.6 ±1.7ab 9.0 ±1.1ab 11.7 ±1.7a <0.010
Y i e l dF o r c e ,( N ) 1 2 .3 ±0.6a 10.3 ±0.4b 12.2 ±0.4ab 11.9 ±0.6ab 12.0 ±2.6ab <0.001
Stiﬀness, (N/mm) 81.4 ± 1.4 75.8 ± 2.7 80.2 ± 3.1 83.0 ± 2.4 84.4 ± 1.2 NS
Energy to Ultimate Force, (mJ) 3.1 ± 0.1 2.7 ± 0.2 3.0 ± 0.2 3.0 ± 0.2 3.3 ± 0.1 NS
Left Tibia (n = 11) (n = 15) (n = 12) (n = 18) (n = 10)
Bone length, (mm) 18.08 ±0.07bc 18.38 ±0.06a 18.26 ±0.03abc 18.33 ±0.06ab 18.07 ±0.04c <0.001
Ultimate Force, (N) 10.5 ± 0.2 9.8 ± 0.2 10.6 ± 0.2 10.4 ± 0.3 10.7 ± 0.4 NS
Failure Force, (N) 4.9 ± 0.9 3.7 ± 0.6 3.3 ± 0.3 4.5 ± 0.6 3.7 ± 0.8 NS
Yield Force, (N) 10.0 ± 0.2 9.1 ± 0.3 10.3 ± 02 9.9 ± 0.3 10.2 ± 0.4 NS
Stiﬀness, (N/mm) 36.2 ±1.1 35.8 ± 0.8 39.1 ±1.1 37.4 ± 0.8 38.5 ± 0.9 NS
Energy to Ultimate Force, (mJ) 2.0 ± 0.1 1.8 ± 0.1 1.8 ± 0.1 1.9 ± 0.1 1.9 ± 0.1 NS
Data represent the group means ± SEM. Diﬀerent letters indicate means that are statistically diﬀerent. NS indicates not signiﬁcant. Samples that rolled on the
supports during mechanical testing were eliminated from the analyses.
Unlike most other bone studies in mice in which the
eﬀects of GEN have been evaluated following subcutaneous
delivery via osmotic pumps or injection regimens [15–
17, 47, 48], this study assessed the eﬀects of daily GEN
consumption on bone. GEN administered at 0.4g/kg of food
to treated mice resulted in consumption levels of 55mg
GEN/kg body weight, or on average 1.2mg GEN/day. This
dose is in keeping with other rodent studies in which 42mg
[49] and 50mg dietary GEN/kg bodyweight/day [50, 51]w a s
evaluated for bone-sparing eﬀects following ovariectomy.
Anderson et al. [52] classiﬁed dietary GEN supplementation
in rats as low (0.5mg/day), intermediate (1.6mg/day), and
high (5.0mg/day) when assessing changes in bone tissue. To
put these supplementary GEN doses into some context with
respect to human intakes, traditional East-Asiatic diets that
are soy-rich supply isoﬂavones ranging from 1mg/kg body-
weight/day [39] to 25-100mg/day [53], whereas the typical
West European and North American diet only supplies a
few milligrams of isoﬂavones per day. Human observational
studies suggest that isoﬂavone eﬀects on BMD are evident
in women consuming >40–60mg/day [54] whereas human
intervention trials demonstrate bone-conserving eﬀects in
women supplemented with 54mg GEN/day or up to 80–
99mg isoﬂavones/day [19, 55, 56].
While VCD-treated mouse bones remained similar to
those of SHM controls for the duration of this study,
VCD-treated mice did appear to better simulate the human
physiological transition to menopause. S + V and SVG
mice underwent a perimenopausal-like period character-
ized by signiﬁcant estrous cycle perturbations compared
to SHM controls based on the vaginal cytology analyses.
The VCD-treated mice also exhibited a gradual or time-
dependent increase in the secretion of the gonadotropin
F S Hc o m p a r e dt oO V Xm i c e .T h i so c c u r sa sar e s u l t
of diminishing levels of ovarian-synthesized estrogen and
inhibin-A episodically disrupting the negative feedback loop
governing the hypothalamic-pituitary-gonadal axis such that
the pituitary persists in secreting FSH [57]. The VCD-treated
mice mimicked the temporal rise in FSH observed in women
that naturally transition to menopause. Evidence exists
to suggest that both ovulation disturbances and elevated
gonadotropin levels during perimenopause are associated
with accelerated bone loss in women [29, 58]. With the
exception of the decrease in vertebral trabecular BV/TV in
SVG relative to SHM mice, signiﬁcant perimenopausal bone
loss was not observed in the VCD-treated mice in this study.
Wright et al. [25] have compared the skeletal eﬀects of
VCD-treated C57Bl/6Hsd mice that took between 38 and
64 days to become acyclic, to ovariectomized and ovary-
intact control mice. Their data indicate that while spinal
BMD (mg/cm2) in VCD-treated mice took 2.9 months after
the event of ovarian follicle depletion to decrease relative
to controls, age-matched OVX mice exhibited a decreased
spinal BMD versus controls as soon as 1 months after
ovariectomy. By 3.4-months postovarian follicle depletion
or OVX, the decline in spinal BMD was similar for VCD-
treatedandOVXmiceandbothmodelsexhibitedBMDsthat
were comparably lower than control mice. These results are
diﬃculttocomparetoourﬁndingsconsideringthatthemice
in the Wright et al. study were dosed with VCD as early as
28-day-old, whereas the mice in our study were dosed at an
age when they are considered to be more skeletally mature.
Given that VCD treatment of sexually immature mice makes
it problematic to determine what changes in bone density
and structure are attributable to perturbations in growth
and development as opposed to bone loss, older mice may
represent a more age-appropriate model for osteoporosis
research. Interestingly, the longitudinal pQCT data collected
for our older mice demonstrated that while cortical BMD of
the tibiae continued to increase in mice up to at least 30-wk-
age, trabecular BMD at the same location declined over the
duration of the experiment.Journal of Osteoporosis 11
Ex vivo μCT analysis performed by Wright et al. in bones
of 5.3-months postmenopausal (i.e., 8.5-months-old VCD-
treated) and intact control mice revealed no signiﬁcant dif-
ferences in trabecular microarchitecture at the distal femur
and in cortical bone parameters at the femoral midshaft.
The fact that our μCT data showed correspondingly low
BV/TV values in 8.5-months-old mice (on average 1-months
afterovarianfollicledepletion)andconsideringnodiﬀerence
between control and VCD-treated mice at the distal femur
was evident collectively suggests that this site may undergo
extensive trabecular bone loss due to age in this mouse strain
making diﬀerences more diﬃcult to detect. The μCT data
are also similar between studies in relation to VCD-treated
and ovary-intact controls at the femoral midshaft, but not
at the 5th lumbar vertebra. Whereas diminished trabecular
morphology was associated with early VCD-treatment in
the Wright study, it was not diﬀerent in the mature VCD-
treated versus SHM mice in the present study 1-month after
ovarian follicle depletion. The shorter duration of ovarian
follicle depletion in our VCD-treated mice may explain this
diﬀerence. Further investigation of skeletally mature VCD-
treated rodents beyond 1-month of ovarian follicle depletion
is warranted to evaluate the practical utility of this model for
osteoporosis research.
Androgens have been determined to have a positive eﬀect
on BMD in postmenopausal women [59]. Research pub-
lished by Rivera et al. [28] conﬁrms the continued androgen-
producing capacity of follicle-depleted ovarian tissue follow-
ing VCD treatment of mice. A major shortcoming associated
with the OVX rodent model that is frequently overlooked
when assessing the eﬃcacy of therapeutics to attenuate
bone loss relates to ovary ablation abolishing the potential
for ovarian androgen synthesis during the menopause-like
state. Activity of the enzyme 17α-hydroxylase/17,20-lyase
cytochrome P450 (P450c17) is required for the production
of androgens in all animals [60]. While humans express
P450c17intheadrenalsandgonads,rodentsexpressp450c17
predominantly in the gonads and it is absent from the
adrenals [61, 62] beyond the embryonic stage of life [63].
The state of estrogen [64] and androgen depletion [25]
attributable to ovariectomy of rodents therefore generates a
relatively more severely compromised sex steroid status than
is typical in either natural menopause or oophorectomy for
women. The concentrations of the androgen androstenodi-
one were wide ranging in the blood samples collected from
SHM, S + V, and SVG mice during wk-9 to wk-18, yet clearly
most prominent in the ovary-intact mice. The presence
of androgens in the VCD-treated mice is likely implicated
in their similarity of bone parameters to control rats, as
opposed to the diﬀerences in bone parameters between OVX
and controls.
In contrast to many women, the lack of an appreciable
amount of bone loss during the perimenopausal transition
to menopause and during early menopause in the VCD-
treated mice could be attributable to a number of factors.
These may include the mouse strain, sample sizes, the VCD
dose/regimen for the age of the mice, and/or the superlative
nutritional history of standard laboratory rodents. Many
rodent diets, especially natural ingredient diets, generally
contain ≥1% dietary calcium which is at least twice the
estimated recommended Ca intake for rodent maintenance
[65, 66]. Traditionally, this situation is unlike one experi-
enced by the majority of women that habitually struggle
to meet adequate Ca intake requirements throughout their
adultlife[67,68].Manipulationoffactorssuchasthesecould
further inﬂuence the results of this experiment.
According to the existing body of research, a carefully
regulatedVCDdosingregimenforrodentsspeciﬁcallytargets
oocyte-containing small preantral ovarian follicles without
toxic eﬀects or abnormalities manifesting in other cells,
tissues, or organs [25, 27, 69, 70]. Fluid-ﬁlled ovarian cysts
are not uncommon in mice, especially as they age and total
ovulation number increases [71]. The ovary abnormalities
observedinsomeofthemiceinthisstudywerenotspeciﬁcto
VCD treatment and may not have even been pathological in
nature. Sentinel mice housed in the same room of the facility
were assessed for potential pathogens and passed a stringent
necropsy inspection report. However, as a precautionary
measure, bone and other data of aﬀected animals were
summarily omitted from all but the food intake analyses due
to group housing.
5. Conclusion
Our study may be the ﬁrst to demonstrate that dietary GEN,
as opposed to injected GEN, provides some modest beneﬁts
to the bones of skeletally mature ovariectomized mice.
However, considering that the OVX mouse is an instanta-
neous model of menopause and negates the postmenopausal
contributions made to the skeleton by ovarian androgens,
this makes it diﬃcult to translate what this may mean for the
majority of women that remain ovary-intact and gradually
transition to menopause. The VCD-treated mouse better
simulates the hormonal milieu and reproductive cycling
changescommensuratewithperimenopauseandmenopause
in women. Yet, based on this investigation, appreciable
changes in bone in response to a VCD-augmented transition
to menopause in mature animals did not occur up to one
month after ovarian follicle depletion. Although this did not
provide an opportunity in which to assess the skeletal eﬀects
of dietary GEN in the VCD-treated mice, we acknowledge
that many potential manipulatable aspects of this rodent
model remain unexplored. With these possibilities in mind,
further investigation is required to determine how applicable
theVCDmodelmaybeforosteoporosisresearch.Asarodent
model to best simulate human menopause, it may be far
superior provided that researchers can take on the additional
cost and time required for VCD-treated mice to experience
signiﬁcant bone loss.
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